Bacillus calmette-guerin substrain tice live antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Bacillus calmette-guerin substrain tice live antigen is a live attenuated vaccine against Mycobacterium bovis.

Brand Names
BCG Vaccine, Tice Bcg
Generic Name
Bacillus calmette-guerin substrain tice live antigen
DrugBank Accession Number
DB10343
Background

Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis for percutaneous use. It is administered to prevent the development of tuberculosis.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Attenuated
Synonyms
  • BCG, Live, Tice Strain

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Abatacept.
AcyclovirThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Acyclovir.
AdalimumabThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Adalimumab.
Adefovir dipivoxilThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Adefovir dipivoxil.
AldesleukinThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Aldesleukin.
AlefaceptThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Alefacept.
AlemtuzumabThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Alemtuzumab.
AltretamineThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Altretamine.
AmantadineThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Amantadine.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Bcg VaccineInjection, powder, lyophilized, for solution50 mg/1PercutaneousMerck Sharp & Dohme Corp.1989-06-21Not applicableUS flag
OncoticePowder, for solution50 mg/1IntravesicalMerck Ltd.1995-12-31Not applicableCanada flag
Tice BcgPowder, for suspension50 mg/50mLIntravesicalMerck Sharp & Dohme Corp.1990-08-24Not applicableUS flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
2XQ558L16Z
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910522
RxNav
221050

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentStage 0 Bladder Urothelial Carcinoma / Stage 0is Bladder Urothelial Carcinoma / Stage I Bladder Urothelial Carcinoma1
3RecruitingTreatmentBladder Cancer, Cancer3
3RecruitingTreatmentHigh-Risk Non-Muscle-Invasive Bladder Cancer1
3WithdrawnPreventionCoronavirus Disease 2019 (COVID‑19)1
2RecruitingSupportive CareBladder Urothelial Carcinoma In Situ / Stage 0a Bladder Cancer AJCC v8 / Stage 0is Bladder Cancer AJCC v8 / Stage I Bladder Cancer AJCC v8 / Superficial Bladder Urothelial Carcinoma / Urothelial Carcinoma Bladder Recurrent1
2, 3Not Yet RecruitingTreatmentMetastatic Cutaneous Melanoma1
1Active Not RecruitingTreatmentRecurrent Bladder Carcinoma / Stage 0a Bladder Urothelial Carcinoma / Stage 0is Bladder Urothelial Carcinoma / Stage I Bladder Cancer1
1CompletedTreatmentBladder Cancer, Cancer1
1CompletedTreatmentTransitional Cell Carcinoma of Bladder1
1, 2CompletedTreatmentBladder Cancer, Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for solutionPercutaneous50 mg/1
Injection, powder, for suspensionIntravesical
Powder, for solutionIntravesical50 mg/1
Powder, for suspensionIntravesical50 mg/50mL
Injection, powder, lyophilized, for suspension50 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 20:03 / Updated on July 28, 2021 07:24